{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:25:29Z","timestamp":1761128729884},"reference-count":80,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,1,12]],"date-time":"2009-01-12T00:00:00Z","timestamp":1231718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The humanized anti\u2010CD52 monoclonal antibody alemtuzumab belongs to the family of Campath\u20101 antibodies, which were initially developed for their ability to prevent graft\u2010<jats:italic>versus<\/jats:italic>\u2010host disease (GVHD) and graft rejection in stem cell transplantation. Alemtuzumab is indicated for the treatment of chronic lymphocytic leukaemia (CLL) and has demonstrated considerable activity in relapsed\/refractory disease and in previously untreated disease. It has been shown to induce minimal residual disease\u2010negative responses as a single agent or as part of consolidation therapy in a meaningful proportion of patients with CLL and has shown promising activity in patients with high\u2010risk cytogenetic markers. Alemtuzumab may also have significant activity in T\u2010cell malignancies, such as mycosis fungoides and T\u2010cell prolymphocytic leukaemia. Recent studies also have evaluated alemtuzumab as part of a conditioning regimen to prevent GVHD in stem cell transplantation. This article reviews our current understanding of alemtuzumab and discusses its emerging role in the treatment of CLL and other haematological malignancies.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2008.07557.x","type":"journal-article","created":{"date-parts":[[2009,1,12]],"date-time":"2009-01-12T08:56:58Z","timestamp":1231750618000},"page":"818-831","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Rediscovering alemtuzumab: current and emerging therapeutic roles"],"prefix":"10.1111","volume":"144","author":[{"given":"John G.","family":"Gribben","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,2,19]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20477"},{"key":"e_1_2_9_3_1","doi-asserted-by":"crossref","first-page":"612a","DOI":"10.1182\/blood.V110.11.2054.2054","article-title":"Emergence of rituximab\u2010fludarabine resistance is associated with changes in CD20 antigen expression and improved response to alemtuzumab therapy in patients with chronic lymphocytic leukemia (CLL)","volume":"110","author":"Ashraf U.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.4.2600"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.012"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61125-8"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4357"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.1071"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1721"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3372"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04265.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.9950"},{"key":"e_1_2_9_14_1","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1200\/jco.2008.26.15_suppl.7053","article-title":"Treatment of patients with relapsed\/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: first safety analysis of the CLL2L trial of the German CLL Study Group","volume":"26","author":"Elter T.","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3389"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11551"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.01023.x"},{"key":"e_1_2_9_18_1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","article-title":"Effect of Campath\u20101H antibody on human hematopoietic progenitors in vitro","volume":"82","author":"Gilleece M.H.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(97)00158-6"},{"key":"e_1_2_9_20_1","first-page":"1476","article-title":"Effect of alemtuzumab on neoplastic B cells","volume":"89","author":"Golay J.","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.3089"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/146532401753174098"},{"key":"e_1_2_9_23_1","first-page":"597","article-title":"Control of graft\u2010versus\u2010host disease and graft rejection by T cell depletion of donor and recipient with Campath\u20101 antibodies. Results of matched sibling transplants for malignant diseases","volume":"13","author":"Hale G.","year":"1994","journal-title":"Bone Marrow Transplantation"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.4.873.873"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90588-0"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1182\/blood.V92.12.4581","article-title":"Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft\u2010versus\u2010host disease and graft rejection","volume":"92","author":"Hale G.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb02203.x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9098"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-0696-y"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.3.231"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404435"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3554"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.205"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000006547"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2004.n.002"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2245"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00143.x"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109057956"},{"key":"e_1_2_9_39_1","first-page":"9","article-title":"CD52 is the \u2018major maturation\u2010associated\u2019 sperm membrane antigen","volume":"2","author":"Kirchhoff C.","year":"1996","journal-title":"Molecular Human Reproduction"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705249"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.7.2419"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.7184"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3729"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.10.3257"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0159"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2802"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404014"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6037"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.021"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2004.10.008"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1105"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2002.n.016"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2005.03.024"},{"key":"e_1_2_9_55_1","first-page":"109a","article-title":"Alemtuzumab for minimal residual disease in CLL","volume":"102","author":"O\u2019Brien S.M.","year":"2003","journal-title":"Blood"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11871"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080010"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184"},{"key":"e_1_2_9_59_1","first-page":"135","volume-title":"Monoclonal Antibody Therapy of Hematologic Malignancies","author":"Osterborg A.","year":"2001"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.450989.x"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1567"},{"key":"e_1_2_9_62_1","first-page":"1435","article-title":"The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53","volume":"90","author":"Osuji N.C.","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0701"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.0680"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.06.119"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.29"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3236"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1998.00615.x"},{"key":"e_1_2_9_69_1","doi-asserted-by":"crossref","first-page":"14a","DOI":"10.1182\/blood.V108.11.34.34","article-title":"Final report of the UKCLL02 trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with flduarabine\u2010refractory CLL (on behalf of the NCRI CLL Trials Subgroup)","volume":"108","author":"Sayala H.A.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-004-0917-0"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200208083470619"},{"key":"e_1_2_9_72_1","doi-asserted-by":"crossref","first-page":"918a","DOI":"10.1182\/blood.V110.11.3120.3120","article-title":"Subcutaneous alemtuzumab (MabCampath) in fludarabine\u2010refractory CLL (CLL2H trial of the GCLLSG)","volume":"110","author":"Stilgenbauer S.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_9_73_1","first-page":"380s","article-title":"The clinical significance of chromosome 17p deletion in chronic lymphocytic leukemia: a study of 180 consecutive patients","volume":"26","author":"Tam C.S.","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-001-0394-7"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)92564-9"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403354"},{"key":"e_1_2_9_77_1","doi-asserted-by":"crossref","first-page":"14a","DOI":"10.1182\/blood.V108.11.31.31","article-title":"Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL","volume":"108","author":"Wierda W.G.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_9_78_1","doi-asserted-by":"crossref","first-page":"628a","DOI":"10.1182\/blood.V110.11.628.628","article-title":"Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high\u2010risk patients with CLL","volume":"110","author":"Wierda W.G.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj2930633"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-007898"},{"key":"e_1_2_9_81_1","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced\u2010dose alemtuzumab treatment in patients with pretreated T\u2010cell lymphoma","volume":"90","author":"Zinzani P.L.","year":"2005","journal-title":"Haematologica"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2008.07557.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2008.07557.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T17:35:37Z","timestamp":1695922537000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2008.07557.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,19]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1111\/j.1365-2141.2008.07557.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07557.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,19]]},"assertion":[{"value":"2009-02-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}